|
|
|
|
Дата |
|---|
| 10:01 |
| 14.01.2026 |
| 13.01.2026 |
| 12.01.2026 |
| 09.01.2026 |
| 08.01.2026 |
| 07.01.2026 |
| 06.01.2026 |
| 05.01.2026 |
| 31.12.2025 |
Bid | Ask |
Open |
Min | Max |
Last |
Legal close |
Avg |
Оборот |
Кол-во сделок |
|---|---|---|---|---|---|---|---|
|
43.01
|
43.02
|
41.10
|
41.10
|
45.95
|
43.01
|
|
|
1 457 707 586.00
|
|
|
|
|
41.10
|
41.10
|
45.95
|
43.01
|
|
|
1 457 707 586.00
|
|
|
|
|
40.62
|
40.62
|
42.96
|
41.83
|
|
|
1 339 704 957.00
|
|
|
|
|
41.50
|
39.99
|
41.55
|
40.38
|
|
|
1 013 089 712.00
|
|
|
|
|
41.92
|
40.72
|
42.35
|
42.11
|
|
|
919 226 363.00
|
|
|
|
|
40.60
|
40.60
|
42.80
|
42.18
|
|
|
1 151 477 609.00
|
|
|
|
|
38.53
|
38.53
|
41.61
|
41.30
|
|
|
1 497 404 325.00
|
|
|
|
|
39.80
|
37.80
|
39.96
|
38.45
|
|
|
1 308 452 984.00
|
|
|
|
|
35.29
|
35.02
|
38.51
|
38.51
|
|
|
1 032 891 743.00
|
|
|
|
|
34.80
|
34.50
|
35.82
|
35.01
|
|
|
590 187 713.00
|
|
Период |
|---|
| 2023, регулярные |
| 2022, регулярные |
| 2021, регулярные |
| 2020, регулярные |
| 2019, регулярные |
| 2018, регулярные |
| 2017, регулярные |
|
Экс-дивидендная дата
|
Закрытие реестра |
Сумма выплаты |
|---|---|---|
|
31.07.2024
|
30.07.2024 |
0.16 CNY |
|
25.07.2023
|
24.07.2023 |
0.4 CNY |
|
08.08.2022
|
05.08.2022 |
0.36 CNY |
|
05.08.2021
|
04.08.2021 |
0.35 CNY |
|
08.06.2020
|
05.06.2020 |
0.34 CNY |
|
10.04.2019
|
09.04.2019 |
0.3 CNY |
|
31.05.2018
|
30.05.2018 |
0.3 CNY |
Joinn Laboratories (China) Co Ltd is a China-based company principally engaged in the provision of pharmaceutical research and development outsourcing services. The Company operates its business through two segments. The Pharmaceutical Research and Development Outsourcing Services segment mainly provides non-clinical safety evaluation services, pharmacodynamic research services, animal pharmacokinetic research services and drug screening services. The Laboratory Animal Production and Marketing segment is principally engaged in the production and sales of laboratory animals such as mice, rats and monkeys as well as their ancillary products.
